Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Oragenics (NYSE American: OGEN) announced its participation at the Emergencies in Medicine Conference in Park City, Utah from February 23-28, 2025. Dr. James Kelly, Chief Medical Officer, will present on the company's concussion treatment advancements, specifically focusing on their "Trigger-to-Treat" program.
Dr. Kelly's presentation will highlight ONP-002, a novel intranasal neurosteroid for acute concussion treatment. The clinical trials incorporate BRAINBox Solutions' multi-marker, multimodality test that combines blood biomarker technology and neurocognitive testing to improve concussion detection and patient stratification.
Dr. Frank Peacock, Meeting Director and Principal Investigator for both BRAINBox and Oragenics' clinical trials, emphasized that early identification of high-risk patients could accelerate recovery and reduce long-term neurological complications.
Oragenics (NYSE American: OGEN) ha annunciato la sua partecipazione alla Conferenza sulle Emergenze in Medicina a Park City, Utah, dal 23 al 28 febbraio 2025. Il Dr. James Kelly, Direttore Medico, presenterà i progressi nel trattamento delle commozioni cerebrali, con un focus particolare sul loro programma Trigger-to-Treat.
La presentazione del Dr. Kelly metterà in evidenza ONP-002, un neurosteroide intranasale innovativo per il trattamento acuto delle commozioni cerebrali. Gli studi clinici integrano il test multimodale e multi-marcatore di BRAINBox Solutions, che combina la tecnologia dei biomarcatori ematici e test neurocognitivi per migliorare la rilevazione delle commozioni cerebrali e la stratificazione dei pazienti.
Il Dr. Frank Peacock, Direttore della Riunione e Investigatore Principale per entrambi gli studi clinici di BRAINBox e Oragenics, ha sottolineato che l'identificazione precoce dei pazienti ad alto rischio potrebbe accelerare il recupero e ridurre le complicazioni neurologiche a lungo termine.
Oragenics (NYSE American: OGEN) anunció su participación en la Conferencia de Emergencias en Medicina en Park City, Utah, del 23 al 28 de febrero de 2025. El Dr. James Kelly, Director Médico, presentará los avances en el tratamiento de conmociones cerebrales, enfocándose específicamente en su programa Trigger-to-Treat.
La presentación del Dr. Kelly destacará ONP-002, un neuroesteroide intranasal novedoso para el tratamiento agudo de conmociones cerebrales. Los ensayos clínicos incorporan la prueba multimodal y de múltiples marcadores de BRAINBox Solutions, que combina tecnología de biomarcadores en sangre y pruebas neurocognitivas para mejorar la detección de conmociones cerebrales y la estratificación de pacientes.
El Dr. Frank Peacock, Director de la Reunión e Investigador Principal de los ensayos clínicos de BRAINBox y Oragenics, enfatizó que la identificación temprana de pacientes de alto riesgo podría acelerar la recuperación y reducir las complicaciones neurológicas a largo plazo.
Oragenics (NYSE American: OGEN)는 2025년 2월 23일부터 28일까지 유타주 파크 시티에서 열리는 의학 응급 상황 회의에 참가한다고 발표했습니다. 제임스 켈리 박사, 최고 의료 책임자는 회사의 뇌진탕 치료 발전에 대해 발표하며, 특히 그들의 Trigger-to-Treat 프로그램에 초점을 맞출 것입니다.
켈리 박사의 발표는 급성 뇌진탕 치료를 위한 혁신적인 비강 내 신경 스테로이드인 ONP-002를 강조할 것입니다. 임상 시험은 BRAINBox Solutions의 다중 마커, 다중 모드 테스트를 통합하여 혈액 바이오마커 기술과 신경 인지 테스트를 결합하여 뇌진탕 감지 및 환자 분류를 개선합니다.
프랭크 피콕 박사, 회의 책임자이자 BRAINBox와 Oragenics의 임상 시험의 주요 연구자는 고위험 환자의 조기 식별이 회복을 가속화하고 장기적인 신경학적 합병증을 줄일 수 있다고 강조했습니다.
Oragenics (NYSE American: OGEN) a annoncé sa participation à la Conférence sur les Urgences en Médecine à Park City, Utah, du 23 au 28 février 2025. Le Dr James Kelly, Directeur Médical, présentera les avancées dans le traitement des commotions cérébrales, en se concentrant spécifiquement sur leur programme Trigger-to-Treat.
La présentation du Dr Kelly mettra en avant ONP-002, un neurostéroïde intranasal novateur pour le traitement aigu des commotions cérébrales. Les essais cliniques intègrent le test multimodal et multi-marqueurs de BRAINBox Solutions, qui combine la technologie des biomarqueurs sanguins et des tests neurocognitifs pour améliorer la détection des commotions cérébrales et la stratification des patients.
Le Dr Frank Peacock, Directeur de la Réunion et Investigateur Principal des essais cliniques de BRAINBox et Oragenics, a souligné que l'identification précoce des patients à haut risque pourrait accélérer la récupération et réduire les complications neurologiques à long terme.
Oragenics (NYSE American: OGEN) gab seine Teilnahme an der Konferenz über Notfälle in der Medizin in Park City, Utah, vom 23. bis 28. Februar 2025 bekannt. Dr. James Kelly, Chief Medical Officer, wird über die Fortschritte bei der Behandlung von Gehirnerschütterungen berichten und sich dabei insbesondere auf ihr Trigger-to-Treat-Programm konzentrieren.
Dr. Kellys Präsentation wird ONP-002, ein neuartiges intranasales Neurosteroid zur akuten Behandlung von Gehirnerschütterungen, hervorheben. Die klinischen Studien integrieren den multimodalen Test von BRAINBox Solutions, der Blutbiomarker-Technologie und neurokognitive Tests kombiniert, um die Erkennung von Gehirnerschütterungen und die Patientenstratifizierung zu verbessern.
Dr. Frank Peacock, Tagungsleiter und Hauptforscher für die klinischen Studien von BRAINBox und Oragenics, betonte, dass die frühzeitige Identifizierung von Hochrisikopatienten die Genesung beschleunigen und langfristige neurologische Komplikationen reduzieren könnte.
- Oragenics is advancing innovative treatments for concussion with their novel intranasal neurosteroid ONP-002
- The company is integrating cutting-edge diagnostic technology from BRAINBox Solutions into their clinical trials
- The Trigger-to-Treat paradigm represents a significant advancement in acute concussion care
- Presentation at a prestigious medical conference indicates growing interest in their approach
- No specific data or preliminary results from the clinical trials were mentioned in the press release
- Timeline for potential regulatory approval or market availability of ONP-002 was not provided
- Financial details or funding status for the ongoing clinical trials were not disclosed
- Competitive landscape and differentiation from other concussion treatments not addressed
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced its participation at the Emergencies in Medicine Conference, where Dr. James Kelly, Chief Medical Officer and Oragenics' Medical Advisory Board Member, will present on the advancement of concussion treatments. The event will be held February 23-28, 2025 in Park City, Utah.
Dr. Kelly’s presentation, titled “The Use of a Novel Intranasal Neurosteroid to Treat Concussion Predicted to Have Poor Outcomes,” will focus on Oragenics' "Trigger-to-Treat" program for concussion, specifically highlighting the development of ONP-002, a novel intranasal neurosteroid for the acute treatment of concussion through the subacute period. His session will provide insight into the ongoing clinical trial protocols that incorporate BRAINBox Solutions’ multi-marker, multimodality test incorporating blood biomarker technology and neurocognitive testing a cutting-edge diagnostic platform designed to improve concussion detection, prognosis and patient stratification.
“We are excited to showcase the progress of ONP-002 and our commitment to advancing concussion treatment,” said Dr. Kelly. “By integrating BRAINBox’s cutting-edge platform into our clinical trials, we aim to establish a new standard of care that enables early intervention and more precise treatment strategies. This meeting brings together leading experts in emergency and neurological medicine, and we look forward to discussing how our technology can enhance clinical decision-making and improve patient outcomes in concussion care.”
Dr. Frank Peacock, Meeting Director and Principal Investigator for both the BRAINBox HeadSmart II clinical trials and Oragenics’ ONP-002 clinical trials, comments, “The ‘Trigger-to-Treat’ paradigm marks a significant advancement in acute concussion care. Early identification of high-risk patients and timely intervention have the potential to not only accelerate recovery but also reduce the risk of long-term neurological complications. By improving diagnostic precision and developing targeted treatment strategies, we are taking critical steps toward preventing chronic neurological disease and transforming concussion management.”
The Emergencies in Medicine Conference brings together leading healthcare professionals and researchers to discuss advancements in emergency and trauma care. This event serves as a platform for experts across various fields to explore innovative solutions that improve patient outcomes, with concussion treatment remaining a key area of focus. For more information, please visit https://emergenciesinmedicine.com/.
Investor Contact
Rich Cockrell
404.736.3838
ogen@cg.capital
About Oragenics, Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
FAQ
What is Oragenics' ONP-002 treatment for concussion?
When will Dr. James Kelly present Oragenics' concussion treatment at the Emergencies in Medicine Conference?
How does Oragenics' Trigger-to-Treat program work for concussion patients?
What technology is Oragenics using in their OGEN clinical trials for concussion treatment?
Who is the Principal Investigator for Oragenics' ONP-002 clinical trials?
What potential benefits does Oragenics' concussion treatment offer according to the February 2025 announcement?
